Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 19/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929522 | 0.92 | ADORA1 (0.82) | ADORA1SLC6A3ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL4426727 | 0.90 | ADORA1 (0.82) | ADORA1SLC6A3 | |
| SCHEMBL14464879 | 0.87 | ADORA1 (0.84) | ADORA1SLC6A3 | |
| SCHEMBL4429778 | 0.86 | ADORA1 (0.62) | ADORA1SLC6A3ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL31409453 | 0.86 | ADORA1 (0.62) | ADORA1SLC6A3ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL4428654 | 0.86 | ADORA1 (0.67) | ADORA1SLC6A3ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL4427010 | 0.86 | ADORA1 (0.74) | ADORA1SLC6A3ALDH1A1 | |
| SCHEMBL4432630 | 0.85 | ADORA1 (0.71) | ADORA1SLC6A3 | |
| SCHEMBL13929771 | 0.85 | ADORA1 (0.62) | ADORA1SLC6A3ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL4427399 | 0.85 | ADORA1 (0.67) | ADORA1SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455785-B1 | SUBSTITUTED 2-THIO-3,5-DICYANO-4-PHENYL-6-AMINOPYRIDINES AND THE USE OF THE SAME | BAYER HEALTHCARE AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007073855-A1 | USE OF ADENOSINE A1 RECEPTOR AGONISTS FOR THE PROTECTION OF RENAL CELLS AGAINST TOXIC EFFECTS CAUSED BY AMINOGLYCOSIDES DURING TREATMENT OF INFECTIOUS DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | disclosed |
| US-20060217373-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2006-09-28 | — | — | US | disclosed |
| US-7109218-B2 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050227972-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | BAYER HEALTHCARE AG (DE) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227972-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | TPMT, QDPR, TUBB6 | ADORA1 998/4885SLC6A3 215/4885ALDH1A1 686/4885 |
| US-20060217373-A1 | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | TPMT, QDPR, TUBB6 | ADORA1 998/4885SLC6A3 215/4885ALDH1A1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.